2016;1:842 3. 128. Lowrie R, Mair FS, Greenlaw N, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33:314 24. 129. Eggink RN, Lenderink AW, Widdershoven JW, et al. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci. 2010;32:759 66. 130. Jain A, Mills P, Nunn LM, et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail. 2005;7:405 10. 131. Bhat S, Kansal M, Kondos GT, et al. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52:724 32. 132. Gourzoulidis G, Kourlaba G, Stafylas P, et al. As- sociation between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy. 2017;121:363 77. 133. Colvin M, Sweitzer NK, Albert NM, et al. Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee. J Card Fail. 2015;21:674 93. 134. A lalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63:747 62. 135. Solomon SD, Claggett B, Desai AS, et al. In uence of ejection fraction on outcomes and ef cacy of sacu- bitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact of global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744. 136. Kaplan A, Streefkerk H, Thorburn C, et al. Com- parison of angioedema in heart failure patients treated with sacubitril/valsartan or enalapril in the PARADIGM- HF Study. J Card Fail. 2016;22:S66 7. J Maddox et al. 137. 